Glatiramer (acetate)

Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, inhibits Experimental autoimmune encephalomyelitis (EAE), and can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression[1][2][3].

Product Specifications

CAS Number

[147245-92-9]

UNSPSC

12352005

Hazard Statement

H315, H317, H319, H334

Target

Others

Type

Reference compound

Related Pathways

Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/glatiramer-acetate.html

Purity

98.0

Solubility

H2O : 50 mg/mL (ultrasonic)

Smiles

OC(CC[C@H](N)C(O)=O)=O.OC([C@@H](N)CC1=CC=C(O)C=C1)=O.OC([C@@H](N)C)=O.NCCCC[C@H](N)C(O)=O.O=C(C)O.[x].[x].[x].[x].[x]

Molecular Formula

(C9H11NO3.C6H14N2O2.C5H9NO4.C3H7NO2) x.xC2H4O2

Precautions

H315, H317, H319, H334

References & Citations

[1]McKeage K. Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review. CNS Drugs. 2015;29 (5) :425-432.|[2]Arnon R, et al. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A. 2004;101 Suppl 2 (Suppl 2) :14593-14598.|[3]Corey-Bloom J, et al. Beneficial effects of glatiramer acetate in Huntington's disease mouse models: Evidence for BDNF-elevating and immunomodulatory mechanisms. Brain Res. 2017;1673:102-110.|[4]Aharoni R, et al. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ [published correction appears in Proc Natl Acad Sci U S A. 2005 Aug 23;102 (34) :12288]. Proc Natl Acad Sci U S A. 2003;100 (24) :14157-14162.|[5]Lalive PH, et al. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs. 2011 May;25 (5) :401-14.